2,720 Shares in Axon Enterprise, Inc $AXON Purchased by Allstate Corp

Allstate Corp acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,720 shares of the biotechnology company’s stock, valued at approximately $1,952,000.

A number of other institutional investors also recently bought and sold shares of AXON. NorthCrest Asset Manangement LLC raised its stake in shares of Axon Enterprise by 5.4% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Axon Enterprise by 2.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 12,103 shares of the biotechnology company’s stock valued at $8,649,000 after acquiring an additional 237 shares during the last quarter. DMC Group LLC increased its holdings in Axon Enterprise by 19.1% during the 3rd quarter. DMC Group LLC now owns 1,116 shares of the biotechnology company’s stock valued at $801,000 after acquiring an additional 179 shares in the last quarter. Amalgamated Bank increased its holdings in Axon Enterprise by 5.6% during the 3rd quarter. Amalgamated Bank now owns 17,260 shares of the biotechnology company’s stock valued at $12,386,000 after acquiring an additional 923 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in Axon Enterprise by 10.8% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 12,100 shares of the biotechnology company’s stock worth $8,683,000 after acquiring an additional 1,175 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $620.52 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The firm has a market capitalization of $48.97 billion, a price-to-earnings ratio of 196.37, a price-to-earnings-growth ratio of 20.02 and a beta of 1.41. Axon Enterprise, Inc has a one year low of $469.24 and a one year high of $885.91. The company has a 50 day moving average price of $573.18 and a 200 day moving average price of $679.22.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter in the previous year, the firm posted $1.45 EPS. The firm’s revenue for the quarter was up 30.6% compared to the same quarter last year. Sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Northcoast Research upgraded shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target on the stock in a research report on Tuesday, January 6th. The Goldman Sachs Group reduced their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Piper Sandler dropped their price target on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $805.71.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $552.60, for a total value of $11,052,000.00. Following the transaction, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. The trade was a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeri Williams sold 100 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $550.63, for a total transaction of $55,063.00. Following the transaction, the director owned 1,316 shares in the company, valued at $724,629.08. This trade represents a 7.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 60,540 shares of company stock worth $34,684,738. 5.70% of the stock is currently owned by insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.